Institutional investors purchased a net $22.7 thousand shares of REGN during the quarter ended September 2016. This may signal that the smart money is gaining interest in this company as the 71.21% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
LOOMIS, SAYLES & CO. LP Bought 1.1 Million shares of Regeneron Pharmaceuticals